Format

Send to

Choose Destination
Nutrition. 2017 Mar;35:100-105. doi: 10.1016/j.nut.2016.11.001. Epub 2016 Nov 22.

Chronic administration of the soluble, nonbacterial fraction of kefir attenuates lipid deposition in LDLr-/- mice.

Author information

1
Pharmaceutical Sciences Graduate Program, Vila Velha University, Vila Velha, Brazil.
2
Laboratory of Translational Physiology, Federal University of Espirito Santo, Vitoria, Brazil; Institute of Education, Science and Technology (IFES), Vila Velha, Brazil.
3
Laboratory of Translational Physiology, Federal University of Espirito Santo, Vitoria, Brazil.
4
Pharmaceutical Sciences Graduate Program, Vila Velha University, Vila Velha, Brazil; Laboratory of Translational Physiology, Federal University of Espirito Santo, Vitoria, Brazil.
5
Department of Clinical and Toxicologic Analyses, Faculty of Pharmaceutical Sciences, University of São Paulo, São Paulo, Brazil.
6
Pharmaceutical Sciences Graduate Program, Vila Velha University, Vila Velha, Brazil; Institute of Education, Science and Technology (IFES), Vila Velha, Brazil.
7
Pharmaceutical Sciences Graduate Program, Vila Velha University, Vila Velha, Brazil. Electronic address: Tadeu.andrade@uvv.br.

Abstract

OBJECTIVES:

Kefir is obtained by the action of acidic bacteria and yeasts that exist in symbiotic association in kefir grains. Recently, this fermented milk drink has been recommended for the treatment of several clinical conditions, such as inflammatory, gastrointestinal, or cardiovascular-related diseases, or a combination of these diseases. However, its effects on atherosclerosis are not yet clear. The aim of this study was to prove that chronic treatment with a soluble, nonbacterial fraction of kefir could reduce the progression of atherosclerosis in low-density lipoprotein receptor-deficient (LDLr-/-) mice.

METHODS:

LDLr-/- mice were divided into four groups as follows: RESULTS: The soluble, nonbacterial fraction of kefir reduced lipid deposition (P < 0.05) independent of hypercholesterolemia. Moreover, kefir was capable of diminishing the circulating proinflammatory intereukin (IL)-6 level and the ratio of tumor necrosis factor-α to IL-10 (50% and 42%, P < 0.05, respectively) and augmenting the antiinflammatory IL-10 level by approximately 74% (P < 0.05).

CONCLUSIONS:

Chronic treatment with a soluble nonbacterial fraction of kefir was able to decrease the lipid deposition in LDLr-/- hypercholesteremic mice, at least in part through modifying the circulating cytokine profile. The beneficial effects of kefir provide new perspectives for its use as an adjuvant in the prevention of atherosclerosis.

KEYWORDS:

Atherosclerosis; Cytokines; Kefir; LDLr(−/−); Probiotics

PMID:
28241975
DOI:
10.1016/j.nut.2016.11.001
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center